Lewis B Silverman

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01
    L B Silverman
    Department of Pediatric Oncology, Dana Farber Cancer Institute, The Division of Hematology Oncology, Children s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Blood 97:1211-8. 2001
  2. pmc Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia
    Lewis B Silverman
    Departments of Pediatric Oncology, Biostatistics, and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 115:1351-3. 2010
  3. pmc Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000)
    L B Silverman
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leukemia 24:320-34. 2010
  4. ncbi request reprint Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment
    Lewis B Silverman
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Children s Hospital, Boston, Massachusetts 02115, USA
    Curr Opin Hematol 10:290-6. 2003
  5. ncbi request reprint Acute lymphoblastic leukemia in infancy
    Lewis B Silverman
    Department of Pediatric Oncology, Dana Farber Cancer Institute and Children s Hospital, Boston, Massachusetts 02115, USA
    Pediatr Blood Cancer 49:1070-3. 2007
  6. pmc Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01
    Jianbiao Zhou
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 110:1607-11. 2007
  7. ncbi request reprint Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation
    Adolfo A Ferrando
    Department of Pediatric Oncology, Mayer 630, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 102:262-8. 2003
  8. pmc Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia
    Alejandro Gutierrez
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 28:3816-23. 2010
  9. pmc Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL
    Lynda M Vrooman
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, 02215, USA
    J Clin Oncol 31:1202-10. 2013
  10. pmc The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium
    Lynda M Vrooman
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Eur J Cancer 47:1373-9. 2011

Research Grants

Detail Information

Publications46

  1. ncbi request reprint Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01
    L B Silverman
    Department of Pediatric Oncology, Dana Farber Cancer Institute, The Division of Hematology Oncology, Children s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Blood 97:1211-8. 2001
    ..The inferior outcome of older children may be due, in part, to increased intolerance of intensive therapy...
  2. pmc Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia
    Lewis B Silverman
    Departments of Pediatric Oncology, Biostatistics, and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 115:1351-3. 2010
    ..This trial was registered at www.clinicaltrials.gov as #NCT00400946...
  3. pmc Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000)
    L B Silverman
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leukemia 24:320-34. 2010
    ..Current studies continue to focus on improving efficacy while minimizing acute and late toxicities...
  4. ncbi request reprint Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment
    Lewis B Silverman
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Children s Hospital, Boston, Massachusetts 02115, USA
    Curr Opin Hematol 10:290-6. 2003
    ....
  5. ncbi request reprint Acute lymphoblastic leukemia in infancy
    Lewis B Silverman
    Department of Pediatric Oncology, Dana Farber Cancer Institute and Children s Hospital, Boston, Massachusetts 02115, USA
    Pediatr Blood Cancer 49:1070-3. 2007
    ..Current research efforts to improve the outcome of MLL-rearranged ALL in infants include clinical trials testing cytarabine-intensive regimens and translational investigations of novel, targeted therapies, such as FLT3-inhibitors...
  6. pmc Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01
    Jianbiao Zhou
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 110:1607-11. 2007
    ....
  7. ncbi request reprint Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation
    Adolfo A Ferrando
    Department of Pediatric Oncology, Mayer 630, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 102:262-8. 2003
    ..Our findings implicate dysregulation of HOX gene family members as a dominant mechanism of leukemic transformation induced by chimeric MLL oncogenes...
  8. pmc Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia
    Alejandro Gutierrez
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 28:3816-23. 2010
    ..To identify children with T-cell acute lymphoblastic leukemia (T-ALL) at high risk of induction chemotherapy failure by using DNA copy number analysis of leukemic cells collected at diagnosis...
  9. pmc Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL
    Lynda M Vrooman
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, 02215, USA
    J Clin Oncol 31:1202-10. 2013
    ..We assessed the toxicity and efficacy of dexamethasone and a novel dosing method of Escherichia coli L-asparaginase (EC-Asnase) in children and adolescents with newly diagnosed acute lymphoblastic leukemia (ALL)...
  10. pmc The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium
    Lynda M Vrooman
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Eur J Cancer 47:1373-9. 2011
    ..We determined the incidence of SMNs in children and adolescents with acute lymphoblastic leukaemia (ALL) who were treated with dexrazoxane...
  11. doi request reprint Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane
    Elly V Barry
    Departments of Pediatric Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1106-11. 2008
    ..We report the absence of an association of SMNs in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01...
  12. doi request reprint Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01
    Deborah P Waber
    Division of Psychology, Department of Psychiatry, Boston Children s Hospital, Boston, Massachusetts Department of Psychiatry, Harvard Medical School, Boston, Massachusetts
    Pediatr Blood Cancer 60:1785-91. 2013
    ....
  13. ncbi request reprint Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis
    Aihong Li
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 103:4602-9. 2004
    ..Molecular pathophysiology appears relevant to clinical outcome in patients who have only productive rearrangements, and specific rearrangement patterns are associated with differences in the tumor biology of childhood ALL...
  14. ncbi request reprint FLT3 mutations in childhood acute lymphoblastic leukemia
    Scott A Armstrong
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 103:3544-6. 2004
    ..These data suggest that patients with hyperdiploid or relapsed ALL might be considered candidates for therapy with newly described small-molecule FLT3 inhibitors...
  15. pmc Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years post-diagnosis
    Deborah P Waber
    Division of Psychology, Department of Psychiatry, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Pediatr Blood Cancer 58:758-65. 2012
    ..We compared neuropsychological outcomes in children treated for Standard Risk (SR) or HR ALL on Dana-Farber Cancer Institute (DFCI) Consortium ALL Protocol 95-01. We also evaluated their performance relative to normative expectations...
  16. doi request reprint The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols
    Rachael F Grace
    Pediatric Hematology Oncology, Children s Hospital Boston, Dana Farber Cancer Institute Harvard Medical School Biostatistics, Dana Farber Cancer Institute Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 152:452-9. 2011
    ..With this management strategy, a history of VTE does not appear to adversely impact prognosis...
  17. pmc H3K79 methylation profiles define murine and human MLL-AF4 leukemias
    Andrei V Krivtsov
    Division of Hematology Oncology, Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 14:355-68. 2008
    ..We thus demonstrate that ectopic H3K79 methylation is a distinguishing feature of murine and human MLL-AF4 ALLs and is important for maintenance of MLL-AF4-driven gene expression...
  18. ncbi request reprint Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols
    Elly Barry
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:813-9. 2007
    ..We report the outcome of adolescents treated on Dana-Farber Cancer Institute (DFCI; Boston, MA) ALL Consortium Protocols conducted between 1991 and 2000...
  19. ncbi request reprint Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification
    Scott A Armstrong
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 3:173-83. 2003
    ..Finally, we developed a mouse model of MLL and used bioluminescent imaging to determine that PKC412 is active against MLL in vivo...
  20. pmc Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia
    Lynda M Vrooman
    Department of Pediatric Oncology, Biostatistics, and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Pediatr Blood Cancer 54:199-205. 2010
    ..We assessed the nadir enzyme activity and tolerability of Erwinia asparaginase, an alternative preparation, in E. coli asparaginase-allergic patients...
  21. ncbi request reprint Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity
    Deborah P Waber
    Department of Psychiatry, Children s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 22:2701-7. 2004
    ....
  22. ncbi request reprint Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience
    John M Goldberg
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 21:3616-22. 2003
    ..T-cell acute lymphoblastic leukemia (T-ALL) accounts for 10% to 15% of newly diagnosed cases of childhood acute lymphoblastic leukemia (ALL). Historically, T-ALL patients have had a worse prognosis than other ALL patients...
  23. ncbi request reprint Childhood acute lymphoblastic leukemia: update on prognostic factors
    Lynda M Vrooman
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Curr Opin Pediatr 21:1-8. 2009
    ..This review highlights recent advances in our understanding of prognostic factors that may be used to refine risk group classification...
  24. ncbi request reprint Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01
    Deborah P Waber
    Division of Psychology, Department of Psychiatry, Children s Hospital, Boston, MA 02115, USA
    J Clin Oncol 25:4914-21. 2007
    ....
  25. doi request reprint Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia
    Reid Merryman
    Harvard Medical School, Boston, Massachusetts, USA
    Pediatr Blood Cancer 59:925-7. 2012
    ..The myelosuppressive effect of ASP should be considered when designing treatment regimens to avoid excessive toxicity and dose reductions of other critical chemotherapy agents...
  26. pmc The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia
    Alejandro Gutierrez
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 118:4169-73. 2011
    ..Our findings provide compelling evidence that BCL11B is a haploinsufficient tumor suppressor that collaborates with all major T-ALL oncogenic lesions in human thymocyte transformation...
  27. doi request reprint Acute lymphoblastic leukemia in adolescents and young adults
    Elly V Barry
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Curr Hematol Malig Rep 3:161-6. 2008
    ..Pilot prospective studies are under way to test the feasibility of administering pediatric ALL regimens to AYAs with ALL, with promising preliminary results...
  28. pmc Inactivation of LEF1 in T-cell acute lymphoblastic leukemia
    Alejandro Gutierrez
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 115:2845-51. 2010
    ..Our findings suggest that LEF1 inactivation is an important step in the molecular pathogenesis of T-ALL in a subset of young children...
  29. pmc Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01
    Christine M Mrakotsky
    Department of Psychiatry, Children s Hospital Boston, Boston, MA, USA
    Pediatr Blood Cancer 57:492-8. 2011
    ..We evaluated acute neurobehavioral side effects of corticosteroid therapy in preschool versus school-age children by obtaining structured reports weekly for 1 month...
  30. pmc Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia
    W Nicholas Haining
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:1749-54. 2005
    ....
  31. ncbi request reprint Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia
    Andrew P Weng
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Science 306:269-71. 2004
    ..These findings greatly expand the role of activated NOTCH1 in the molecular pathogenesis of human T-ALL and provide a strong rationale for targeted therapies that interfere with NOTCH signaling...
  32. ncbi request reprint Management of an anaphylactoid reaction to methotrexate with a stepwise graded challenge
    Andrew J MacGinnitie
    Division of Allergy Immunology, Children s Hospital, Boston, MA 02446, USA
    Pediatr Allergy Immunol 14:409-11. 2003
    ..Because weekly methotrexate therapy is an important component of continuation chemotherapy for pediatric ALL, a stepwise graded challenge was employed to achieve drug tolerance...
  33. ncbi request reprint Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01
    D P Waber
    Division of Psychology, The Children s Hospital, Boston, Massachusetts 02115, USA
    Cancer 92:15-22. 2001
    ..Efficacy and toxicity were evaluated in relation to patient age at diagnosis (age < or > or = 36 months)...
  34. ncbi request reprint Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia
    W Nicholas Haining
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Exp Hematol 33:286-94. 2005
    ....
  35. ncbi request reprint Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residu
    Aihong Li
    Dept of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:4520-6. 2003
    ..In some cases the leukemic progenitor cell might arise earlier in lineage before DHJH recombination but retain the capacity to further differentiate into cells capable of altering the pattern of Ig and/or TCR rearrangements...
  36. ncbi request reprint Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1
    Scott J Rodig
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Hematol 83:116-21. 2008
    ..Persistent expression of NOTCH1 in such tumors suggests that Notch pathway inhibitors could have a role in the treatment of these unusual neoplasms...
  37. ncbi request reprint Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment
    Virginia Kimball Dalton
    Department of Medicine, Children s Hospital, Boston, MA 02115, USA
    J Clin Oncol 21:2953-60. 2003
    ....
  38. ncbi request reprint MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
    Scott A Armstrong
    Departments of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 30:41-7. 2002
    ..Establishing that MLL is a unique entity is critical, as it mandates the examination of selectively expressed genes for urgently needed molecular targets...
  39. pmc High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia
    Alejandro Gutierrez
    Department of Pediatric Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 114:647-50. 2009
    ..These findings add significant support to the rationale for the development of therapies targeting the PTEN-PI3K-AKT pathway in T-ALL...
  40. ncbi request reprint Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01
    Jean Marie LeClerc
    Division of Hematology Oncology, Hopital Sainte Justine, Montreal, Quebec, Canada
    J Clin Oncol 20:237-46. 2002
    ..To improve efficacy and reduce toxicity of treatment for children with acute lymphoblastic leukemia...
  41. ncbi request reprint The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia
    Steven E Lipshultz
    Department of Pediatrics, University of Miami School of Medicine, Holtz Children s Hospital of the University of Miami Jackson Memorial Medical Center and the Sylvester Comprehensive Cancer Center, Miami 33101, USA
    N Engl J Med 351:145-53. 2004
    ..Doxorubicin chemotherapy is very effective in children with acute lymphoblastic leukemia (ALL) but also injures myocardial cells. Dexrazoxane, a free-radical scavenger, may protect the heart from doxorubicin-associated damage...
  42. ncbi request reprint Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias
    Aihong Li
    Department of Medical Biosciences, Pathology, Umea University, Umea, Sweden
    Br J Haematol 131:185-92. 2005
    ..41) and quantitative MRD assessment at the early time points may not be predictive of outcome. Novel treatment strategies are required to improve the outcome in this poor prognosis subset of children with ALL...
  43. pmc Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01
    Mignon L Loh
    Department of Pediatrics, Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Blood 107:4508-13. 2006
    ..However, factors such as age at diagnosis and presenting leukocyte count should be taken into consideration when treating this group of patients...
  44. pmc Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
    Albert Moghrabi
    Division of Hematology and Oncology, Sainte Justine Hospital, University of Montreal, Quebec, Canada
    Blood 109:896-904. 2007
    ....
  45. ncbi request reprint Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region
    Ching Hon Pui
    St Jude Children s Research Hospital and the University of Tennessee, College of Medicine, Memphis, TN 38105, USA
    Lancet 359:1909-15. 2002
    ....
  46. pmc Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia
    James B Nachman
    The University of Chicago Comer Children s Hospital, IL 60637, USA
    Blood 110:1112-5. 2007
    ..Children and adolescents with ALL and hypodiploidy with fewer than 44 chromosomes have a poor outcome despite contemporary therapy...

Research Grants1

  1. Pharmacogenetics of Asparaginase-Induced Pancreatitis
    Lewis Silverman; Fiscal Year: 2007
    ..abstract_text> ..